FDA declines approval for monthly MS injection by Viatris (NASDAQ:VTRS) and Mapi Pharma

Grafa03-11

The U.S. Food and Drug Administration (FDA) has not approved the once-a-month injection GA Depot, aimed at treating relapsing forms of multiple sclerosis (MS), developed by Viatris (NASDAQ:VTRS) and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2418531583?lang=en_US&edition=fundamental","thumbnail":"https://images.grafa.com/grafa/media-194971-638457543175793274.jpg","is_english":true,"pubTime":"2024-03-11 19:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2418531583","market":"us","top_or_hot":-1,"title":"FDA declines approval for monthly MS injection by Viatris (NASDAQ:VTRS) and Mapi Pharma","media":"Grafa","content":"<div>\n<p>The U.S. Food and Drug Administration (FDA) has not approved the once-a-month injection GA Depot, aimed at treating relapsing forms of multiple sclerosis (MS), developed by Viatris (NASDAQ:VTRS) and ...</p>\n\n<a href=\"https://grafa.com/news/fda-declines-approval-for-monthly-ms-injection-by-viatris--nasdaq-vtrs--and-mapi-pharma-194971\">Source Link</a>\n\n</div>\n","source":"grafa_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA declines approval for monthly MS injection by Viatris (NASDAQ:VTRS) and Mapi Pharma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA declines approval for monthly MS injection by Viatris (NASDAQ:VTRS) and Mapi Pharma\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-11 19:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://grafa.com/news/fda-declines-approval-for-monthly-ms-injection-by-viatris--nasdaq-vtrs--and-mapi-pharma-194971><strong>Grafa</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA) has not approved the once-a-month injection GA Depot, aimed at treating relapsing forms of multiple sclerosis (MS), developed by Viatris (NASDAQ:VTRS) and ...</p>\n\n<a href=\"https://grafa.com/news/fda-declines-approval-for-monthly-ms-injection-by-viatris--nasdaq-vtrs--and-mapi-pharma-194971\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://grafa.com/news/fda-declines-approval-for-monthly-ms-injection-by-viatris--nasdaq-vtrs--and-mapi-pharma-194971","article_id":"2418531583","we_media_id":null,"thumbnails":["https://images.grafa.com/grafa/media-194971-638457543175793274.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2418531583","pubTimestamp":1710157510,"sourceInfo":{"source_id":"grafa_news","name":"Grafa"},"weMediaInfo":null,"summary":"The U.S. Food and Drug Administration  has not approved the once-a-month injection GA Depot, aimed at treating relapsing forms of multiple sclerosis , developed by Viatris  and Mapi Pharma.This decision comes as a setback for the two firms, who are now assessing the FDA's complete response letter to understand their future course of action.GA Depot is designed as a long-acting version of glatiramer acetate, a drug already approved for relapsing MS under the brand name Copaxone, which is produced by Teva Pharmaceutical Industries.The intention behind GA Depot was to offer a less frequent, monthly injection option to improve adherence and convenience for patients managing this chronic condition.","collect":0,"end_time":0,"defaultTopTitle":"grafa.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H",".IXIC":"NASDAQ Composite","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0106831901.USD":"贝莱德世界金融基金A2","BK4007":"制药","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","LU0971096721.USD":"富达环球金融服务 A","BK4588":"碎股","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","NDAQ":"纳斯达克OMX交易所","BK4581":"高盛持仓","BK4504":"桥水持仓","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","BK4112":"金融交易所和数据","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","MS":"摩根士丹利","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","BK4127":"投资银行业与经纪业","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4583":"猴痘概念","VTRS":"Viatris Inc.","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"FDA拒绝批准Viatris（纳斯达克：VTRS）和Mapi Pharma每月注射MS","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTRS":1,"NDAQ":1,"MS":1,".IXIC":1},"content_text":"The U.S. Food and Drug Administration (FDA) has not approved the once-a-month injection GA Depot, aimed at treating relapsing forms of multiple sclerosis (MS), developed by Viatris (NASDAQ:VTRS) and Mapi Pharma.\nThis decision comes as a setback for the two firms, who are now assessing the FDA's complete response letter to understand their future course of action.\nGA Depot is designed as a long-acting version of glatiramer acetate, a drug already approved for relapsing MS under the brand name Copaxone, which is produced by Teva Pharmaceutical Industries.\nThe intention behind GA Depot was to offer a less frequent, monthly injection option to improve adherence and convenience for patients managing this chronic condition.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2418531583"}